Research
Hormonal
Semaglutide, a GLP-1 receptor agonist, demonstrated much greater weight loss than previous medications.
Practitioners may consider semaglutide as a more effective option for weight loss in obese patients.
StrongSupportsmedium confidence
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved in 2021, demonstrated much greater weight loss than previous medications.
Why this rating
The claim is based on the approval and results of a specific medication.
Source
<scp>Glucagon‐like peptide</scp>‐1, glucose‐dependent insulinotropic polypeptide, and glucagon receptor poly‐agonists: a new era in obesity pharmacotherapy
Is‐haq O. Malik et al. · Obesity · 2022
otherCited 11×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →